A large multi-omics study of Angioimmunoblastic T-cell lymphoma (AITL) analyzed 174 patient cases and used patient-derived mouse models to better understand this aggressive blood cancer. Researchers found that the disease is driven mainly by genetic changes affecting epigenetic regulation, T-cell receptor signaling, and the PI3K/AKT pathway. The most frequent mutations included TET2 (81%), DNMT3A (31%), and IDH2 (28%), while the RHOA G17V mutation appeared in about 61% of cases. Patients carrying multiple mutations in these key genes had significantly worse survival.
The study also highlighted the importance of the tumor microenvironment. Tumors containing higher levels of myeloid immune cells were associated with poorer outcomes. In addition, about 70% of cases showed activity of Epstein–Barr virus (EBV), which was linked to inferior survival, although it did not appear to directly drive B-cell growth in the tumors.
Using patient-derived xenograft mouse models, researchers observed that loss of TET2 may act as an early driver of the disease, with tumors becoming more aggressive over time. The findings suggest that targeting the PI3K pathway—for example with PI3K inhibitors such as duvelisib—may be an effective treatment strategy. Combining epigenetic therapies with signaling inhibitors could further improve outcomes for patients with this difficult-to-treat lymphoma.